Hepion Pharmaceuticals Announces Reverse Stock Split
March 14, 2025 08:30 ET
|
Hepion Pharmaceuticals, Inc.
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage...
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
March 10, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
March 07, 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
Plus Therapeutics Announces New Employment Inducement Grants
March 05, 2025 16:01 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain
February 27, 2025 09:45 ET
|
BioRestorative Therapies, Inc
– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease setting – – IND clearance expands Company’s advanced clinical pipeline...
BioRestorative Announces Updated Time for February 27th Webcasted Conference Call to Discuss Clinical Pipeline Update
February 26, 2025 20:15 ET
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused...
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement
February 25, 2025 07:00 ET
|
GT Biopharma, Inc.
SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics...
LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
February 11, 2025 08:42 ET
|
Lixte Biotechnology Holdings, Inc.
PASADENA, CALIF., Feb. 11, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced...
BRTX-100 Front and Center at ORS 2025
February 10, 2025 07:00 ET
|
BioRestorative Therapies, Inc
– New blinded preliminary BRTX-100 data described this past Saturday at prestigious “2025 Winners in Industry Innovations in MSK Health” presentation – – Among other positive preliminary data...
Bioxytran Secures $1.6 million SPA to Extinguish Note & Fund Clinical Development
January 22, 2025 09:00 ET
|
BIOXYTRAN, INC.
- Repurchasing all convertible note overhang, and - Funding pre-clinical and clinical trials - Management forfeiting $460,000 in accrued payroll BOSTON, MASSACHUSETTS, Jan. 22, 2025 (GLOBE...